ARC sponsored Satellite Symposium at HFSA
For the third year running, ARC is supporting a CME Satellite Symposium at the Heart Failure Society of America (HFSA) conference. "Avoiding the pitfalls of diagnosing and treating cardiac ATTR amyloidosis" will be held on Sunday evening, September 15, at...
Read More
Publication of cardiac ATTR amyloidosis diagnosis guidelines
ARC-supported consensus best practices guidelines for the diagnosis of cardiac ATTR amyloidosis published in the journal of the American Heart Association, Circulation:Heart Failure. (more…)
Read More
Research opportunity from hom
Opportunity to Advance hATTR Amyloidosis Research from Home
Prothena has teamed up with Sanguine, a provider of at-home clinical research services, to give you the opportunity to help advance hATTR Amyloidosis research from home. (more…)
Read More
FDA appoints Public Private Partnership Liaison to ARC
To focus on the challenges faced by AL amyloidosis, a particularly complex and multi-systemic disease, and bridge the gaps in drug discovery and development . (more…)
Read More
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) approved by FDA
This represents the first FDA approved treatment in ATTR-CM for both the wild-type and hereditary forms of ATTR amyloidosis. (more…)
Read More

320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170

ARC is a 501(c)(3) nonprofit organization